Novo to Fight Back With New Products to Regain Ground in China

  • Newer Novo drugs expected to hit market within couple of years
  • About 114 million Chinese are estimated to have diabetes

Novo Nordisk A/S, the world’s largest maker of insulin, expects to roll out new diabetes treatments in China within a couple of years, helping the company take on competition that’s eroded its share of the local market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.